Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Nivolumab in Early Stage Classical Hodgkin Lymphoma
NCT03712202Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Nov 2018
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brentuximab vedotin and nivolumab in classical Hodgkin lymphoma (cHL) (4 arms), sponsored by City of Hope. Primary endpoint: 18-month Progression-free Survival. Started Nov 2018; status: active, not recruiting.
02
Drugs
brentuximab vedotinnivolumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03712202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712202.